Teens Suffer From Migraines.
A predetermined type of therapy helps convert the number of migraines and migraine-related disabilities in children and teens, according to a new study. The findings provision strong evidence for the use of "cognitive behavioral therapy" - which includes training in coping with injure - in managing chronic migraines in children and teens, said con leader Scott Powers, of Cincinnati Children's Hospital Medical Center, and colleagues. The remedy should be routinely offered as a first-line treatment, along with medications.
More than 2 percent of adults and about 1,75 percent of children have lasting migraines, according to the study, which was published in the Dec 25, 2013 stream of the Journal of the American Medical Association. But there are no treatments approved by the US Food and Drug Administration to crush these debilitating headaches in young people, the researchers said. The scan included 135 youngsters, aged 10 to 17, who had migraines 15 or more days a month.
Showing posts with label therapy. Show all posts
Showing posts with label therapy. Show all posts
Saturday 8 February 2020
Tuesday 24 December 2019
New Research In The Treatment Of Cancer Of Immune System
New Research In The Treatment Of Cancer Of Immune System.
New explore provides more display that treating certain lymphoma patients with an valuable drug over the long term helps them go longer without symptoms. But the drug, called rituximab (Rituxan), does not seem to significantly development life span, raising questions about whether it's worth taking. People with lymphoma who are in maintenance treatment "really need a discussion with their oncologist," said Dr Steven T Rosen, cicerone of the Robert H Lurie Comprehensive Cancer Center at Northwestern University in Chicago. The contemplation involved people with follicular lymphoma, one of the milder forms of non-Hodgkin lymphoma, a locution that refers to cancers of the immune system.
Though it can be fatal, most individuals live for at least 10 years after diagnosis. There has been debate over whether people with the disease should kill Rituxan as maintenance therapy after their initial chemotherapy. In the study, which was funded in part by F Hoffmann-La Roche, a pharmaceutical throng that sells Rituxan, roughly half of the 1,019 participants took Rituxan, and the others did not. All at one time had taken the drug right after receiving chemotherapy.
In the next three years, the scan found, people taking the drug took longer, on average, to expand symptoms. Three-quarters of them made it to the three-year mark without progression of their illness, compared with about 58 percent of those who didn't snitch the drug. But the death rate over three years remained about the same, according to the report, published online Dec 21 2010 in The Lancet.
New explore provides more display that treating certain lymphoma patients with an valuable drug over the long term helps them go longer without symptoms. But the drug, called rituximab (Rituxan), does not seem to significantly development life span, raising questions about whether it's worth taking. People with lymphoma who are in maintenance treatment "really need a discussion with their oncologist," said Dr Steven T Rosen, cicerone of the Robert H Lurie Comprehensive Cancer Center at Northwestern University in Chicago. The contemplation involved people with follicular lymphoma, one of the milder forms of non-Hodgkin lymphoma, a locution that refers to cancers of the immune system.
Though it can be fatal, most individuals live for at least 10 years after diagnosis. There has been debate over whether people with the disease should kill Rituxan as maintenance therapy after their initial chemotherapy. In the study, which was funded in part by F Hoffmann-La Roche, a pharmaceutical throng that sells Rituxan, roughly half of the 1,019 participants took Rituxan, and the others did not. All at one time had taken the drug right after receiving chemotherapy.
In the next three years, the scan found, people taking the drug took longer, on average, to expand symptoms. Three-quarters of them made it to the three-year mark without progression of their illness, compared with about 58 percent of those who didn't snitch the drug. But the death rate over three years remained about the same, according to the report, published online Dec 21 2010 in The Lancet.
Monday 9 December 2019
A New Approach In The Treatment Of Leukemia
A New Approach In The Treatment Of Leukemia.
An speculative psychoanalysis that targets the immune system might offer a new way to treat an often humdrum form of adult leukemia, a preliminary study suggests. The research involved only five adults with repetitious B-cell acute lymphoblastic leukemia (ALL), a cancer of the blood and bone marrow. ALL progresses quickly, and patients can meet one's Maker within weeks if untreated. The typical to begin treatment is three separate phases of chemotherapy drugs. For many patients, that beats back the cancer.
But it often returns. At that point, the only promise for long-term survival is to have another round of chemo that wipes out the cancer, followed by a bone marrow transplant. But when the sickness recurs, it is often resistant to many chemo drugs, explained Dr Renier Brentjens, an oncologist at Memorial Sloan-Kettering Cancer Center in New York City.
So, Brentjens and his colleagues tested a discrete approach. They took safe system T-cells from the blood of five patients, then genetically engineered the cells to swift so-called chimeric antigen receptors (CARs), which advise the T-cells recognize and destroy ALL cells. The five patients received infusions of their tweaked T-cells after having required chemotherapy.
All five despatch saw a complete remission - within eight days for one patient, the researchers found. Four patients went on to a bone marrow transplant, the researchers reported March 20 in the memoir Science Translational Medicine. The fifth was unqualified because he had heart disease and other health conditions that made the move too risky.
And "To our amazement, we got a full and a very rapid elimination of the tumor in these patients," said Dr Michel Sadelain, another Sloan-Kettering researcher who worked on the study. Many questions remain, however. And the healing - known as adoptive T-cell remedy - is not available case of the research setting. "This is still an experimental therapy".
And "But it's a promising therapy". In the United States, silent to 6100 people will be diagnosed with ALL this year, and more than 1400 will die, according to the National Cancer Institute. ALL most often arises in children, but adults profit for about three-quarters of deaths.
Most cases of ALL are the B-cell form, and Brentjens said about 30 percent of grown-up patients are cured. When the cancer recurs, patients have a swallow at long-term survival if they can get a bone marrow transplant. But if their cancer resists the pre-transplant chemo, the attitude is grim.
An speculative psychoanalysis that targets the immune system might offer a new way to treat an often humdrum form of adult leukemia, a preliminary study suggests. The research involved only five adults with repetitious B-cell acute lymphoblastic leukemia (ALL), a cancer of the blood and bone marrow. ALL progresses quickly, and patients can meet one's Maker within weeks if untreated. The typical to begin treatment is three separate phases of chemotherapy drugs. For many patients, that beats back the cancer.
But it often returns. At that point, the only promise for long-term survival is to have another round of chemo that wipes out the cancer, followed by a bone marrow transplant. But when the sickness recurs, it is often resistant to many chemo drugs, explained Dr Renier Brentjens, an oncologist at Memorial Sloan-Kettering Cancer Center in New York City.
So, Brentjens and his colleagues tested a discrete approach. They took safe system T-cells from the blood of five patients, then genetically engineered the cells to swift so-called chimeric antigen receptors (CARs), which advise the T-cells recognize and destroy ALL cells. The five patients received infusions of their tweaked T-cells after having required chemotherapy.
All five despatch saw a complete remission - within eight days for one patient, the researchers found. Four patients went on to a bone marrow transplant, the researchers reported March 20 in the memoir Science Translational Medicine. The fifth was unqualified because he had heart disease and other health conditions that made the move too risky.
And "To our amazement, we got a full and a very rapid elimination of the tumor in these patients," said Dr Michel Sadelain, another Sloan-Kettering researcher who worked on the study. Many questions remain, however. And the healing - known as adoptive T-cell remedy - is not available case of the research setting. "This is still an experimental therapy".
And "But it's a promising therapy". In the United States, silent to 6100 people will be diagnosed with ALL this year, and more than 1400 will die, according to the National Cancer Institute. ALL most often arises in children, but adults profit for about three-quarters of deaths.
Most cases of ALL are the B-cell form, and Brentjens said about 30 percent of grown-up patients are cured. When the cancer recurs, patients have a swallow at long-term survival if they can get a bone marrow transplant. But if their cancer resists the pre-transplant chemo, the attitude is grim.
Thursday 5 December 2019
Acupuncture Can Treat Some Types Of Amblyopia
Acupuncture Can Treat Some Types Of Amblyopia.
Acupuncture may be an operative situation to treat older children struggling with a certain form of lazy eye, experimental research from China suggests, although experts say more studies are needed. Lazy eye (amblyopia) is essentially a pomp of miscommunication between the brain and the eyes, resulting in the favoring of one eye over the other, according to the National Eye Institute. The haunt authors noted that anywhere from less than 1 percent to 5 percent of colonize worldwide are affected with the condition. Of those, between one third and one half have a typeface of lazy eye known as anisometropia, which is caused by a difference in the degree of nearsightedness or farsightedness between the two eyes.
Standard remedying for children involves eyeglasses or contact lens designed to correct heart issues. However, while this approach is often successful in younger children (between the ages of 3 and 7), it is top among only about a third of older children (between the ages of 7 and 12). For the latter group, doctors will often room a patch over the "good" eye temporarily in addition to eyeglasses, and curing success is typically achieved in two-thirds of cases.
Children, however, often have trouble adhering to plat therapy, the treatment can bring emotional issues for some and a reverse form of lazy eye can also hold root, the researchers said. Study author Dr Dennis SC Lam, from the sphere of influence of ophthalmology and visual sciences and Institute of Chinese Medicine at the Joint Shantou International Eye Center of Shantou University and Chinese University of Hong Kong, and his colleagues gunshot their observations in the December emanate of the Archives of Ophthalmology.
In the search for a better option than patch therapy, Lam and his associates set out to search the potential benefits of acupuncture, noting that it has been used to treat dry eye and myopia. Between 2007 and 2009, Lam and his colleagues recruited 88 children between the ages of 7 and 12 who had been diagnosed with anisometropia.
About half the children were treated five times a week with acupuncture, targeting five unambiguous acupuncture needle insertion points (located at the surpass of the intelligence and the eyebrow region, as well as the legs and hands). The other half were given two hours a daylight of field therapy, combined with a minimum of one hour per day of near-vision exercises such as reading.
After about four months of treatment, the digging team found that overall visual acuity improved markedly more among the acupuncture body relative to the patch group. In fact, they noted that while lazy eye was successfully treated in nearly 42 percent of the acupuncture patients, that silhouette dropped to less than 17 percent in the midst the patch patients.
Acupuncture may be an operative situation to treat older children struggling with a certain form of lazy eye, experimental research from China suggests, although experts say more studies are needed. Lazy eye (amblyopia) is essentially a pomp of miscommunication between the brain and the eyes, resulting in the favoring of one eye over the other, according to the National Eye Institute. The haunt authors noted that anywhere from less than 1 percent to 5 percent of colonize worldwide are affected with the condition. Of those, between one third and one half have a typeface of lazy eye known as anisometropia, which is caused by a difference in the degree of nearsightedness or farsightedness between the two eyes.
Standard remedying for children involves eyeglasses or contact lens designed to correct heart issues. However, while this approach is often successful in younger children (between the ages of 3 and 7), it is top among only about a third of older children (between the ages of 7 and 12). For the latter group, doctors will often room a patch over the "good" eye temporarily in addition to eyeglasses, and curing success is typically achieved in two-thirds of cases.
Children, however, often have trouble adhering to plat therapy, the treatment can bring emotional issues for some and a reverse form of lazy eye can also hold root, the researchers said. Study author Dr Dennis SC Lam, from the sphere of influence of ophthalmology and visual sciences and Institute of Chinese Medicine at the Joint Shantou International Eye Center of Shantou University and Chinese University of Hong Kong, and his colleagues gunshot their observations in the December emanate of the Archives of Ophthalmology.
In the search for a better option than patch therapy, Lam and his associates set out to search the potential benefits of acupuncture, noting that it has been used to treat dry eye and myopia. Between 2007 and 2009, Lam and his colleagues recruited 88 children between the ages of 7 and 12 who had been diagnosed with anisometropia.
About half the children were treated five times a week with acupuncture, targeting five unambiguous acupuncture needle insertion points (located at the surpass of the intelligence and the eyebrow region, as well as the legs and hands). The other half were given two hours a daylight of field therapy, combined with a minimum of one hour per day of near-vision exercises such as reading.
After about four months of treatment, the digging team found that overall visual acuity improved markedly more among the acupuncture body relative to the patch group. In fact, they noted that while lazy eye was successfully treated in nearly 42 percent of the acupuncture patients, that silhouette dropped to less than 17 percent in the midst the patch patients.
Tuesday 26 November 2019
Slowly Progressive Prostate Cancer Need To Be Watched Instead Of Treatment
Slowly Progressive Prostate Cancer Need To Be Watched Instead Of Treatment.
For patients with prostate cancer that has a bawdy imperil of progression, effectual surveillance, also known as "watchful waiting," may be a suitable treatment option, according to a large-scale study from Sweden. The publication of how (or whether) to treat localized prostate cancer is controversial because, especially for older men, the tumor may not ripen far enough to cause real trouble during their remaining expected lifespan. In those cases, deferring care until there are signs of disease progression may be the better option.
The researchers looked at almost 6900 patients from the National Prostate Cancer Registry Sweden, period 70 or younger, who had localized prostate cancer and a dejected or intermediate risk that the cancer would progress. From 1997 through December 2002, over 2000 patients were assigned to animated surveillance, close to 3400 underwent thorough prostatectomy (removal of the prostate and some surrounding tissue), and more than 1400 received radiation therapy.
For patients with prostate cancer that has a bawdy imperil of progression, effectual surveillance, also known as "watchful waiting," may be a suitable treatment option, according to a large-scale study from Sweden. The publication of how (or whether) to treat localized prostate cancer is controversial because, especially for older men, the tumor may not ripen far enough to cause real trouble during their remaining expected lifespan. In those cases, deferring care until there are signs of disease progression may be the better option.
The researchers looked at almost 6900 patients from the National Prostate Cancer Registry Sweden, period 70 or younger, who had localized prostate cancer and a dejected or intermediate risk that the cancer would progress. From 1997 through December 2002, over 2000 patients were assigned to animated surveillance, close to 3400 underwent thorough prostatectomy (removal of the prostate and some surrounding tissue), and more than 1400 received radiation therapy.
Wednesday 11 April 2018
The Impact Of Rituxan For The Treatment Of Follicular Lymphoma
The Impact Of Rituxan For The Treatment Of Follicular Lymphoma.
New scrutinization provides more affirmation that treating certain lymphoma patients with an high-priced drug over the long term helps them go longer without symptoms. But the drug, called rituximab (Rituxan), does not seem to significantly addition life span, raising questions about whether it's worth taking. People with lymphoma who are all things maintenance treatment "really need a discussion with their oncologist," said Dr Steven T Rosen, gaffer of the Robert H Lurie Comprehensive Cancer Center at Northwestern University in Chicago. The mug up involved people with follicular lymphoma, one of the milder forms of non-Hodgkin lymphoma, a period that refers to cancers of the immune system.
Though it can be fatal, most woman in the street live for at least 10 years after diagnosis. There has been debate over whether people with the disease should adopt Rituxan as maintenance therapy after their initial chemotherapy. In the study, which was funded in part by F Hoffmann-La Roche, a pharmaceutical assembly that sells Rituxan, roughly half of the 1019 participants took Rituxan, and the others did not. All once upon a time had taken the drug right after receiving chemotherapy.
In the next three years, the look found, people taking the drug took longer, on average, to originate symptoms. Three-quarters of them made it to the three-year mark without progression of their illness, compared with about 58 percent of those who didn't use the drug. But the death rate over three years remained about the same, according to the report, published online Dec 21 2010 in The Lancet.
New scrutinization provides more affirmation that treating certain lymphoma patients with an high-priced drug over the long term helps them go longer without symptoms. But the drug, called rituximab (Rituxan), does not seem to significantly addition life span, raising questions about whether it's worth taking. People with lymphoma who are all things maintenance treatment "really need a discussion with their oncologist," said Dr Steven T Rosen, gaffer of the Robert H Lurie Comprehensive Cancer Center at Northwestern University in Chicago. The mug up involved people with follicular lymphoma, one of the milder forms of non-Hodgkin lymphoma, a period that refers to cancers of the immune system.
Though it can be fatal, most woman in the street live for at least 10 years after diagnosis. There has been debate over whether people with the disease should adopt Rituxan as maintenance therapy after their initial chemotherapy. In the study, which was funded in part by F Hoffmann-La Roche, a pharmaceutical assembly that sells Rituxan, roughly half of the 1019 participants took Rituxan, and the others did not. All once upon a time had taken the drug right after receiving chemotherapy.
In the next three years, the look found, people taking the drug took longer, on average, to originate symptoms. Three-quarters of them made it to the three-year mark without progression of their illness, compared with about 58 percent of those who didn't use the drug. But the death rate over three years remained about the same, according to the report, published online Dec 21 2010 in The Lancet.
Monday 12 March 2018
New Ways Of Treating Prostate Cancer And Ovarian Cancer
New Ways Of Treating Prostate Cancer And Ovarian Cancer.
New probe supports unconventional ways to treat ovarian and prostate cancer, while producing a dejection for those with a certain form of colon cancer. Both the ovarian and prostate cancer trials could replace clinical practice, with more women taking the drug bevacizumab (Avastin) to combat the disease in its advanced stages and more men getting shedding therapy for locally advanced prostate cancer, according to researchers who presented the findings Sunday at the American Society of Clinical Oncology (ASCO) annual intersection in Chicago. A third trial, looking at the effectiveness of cetuximab (Erbitux) in treating sure colon cancer patients, found the numb made little difference to their survival.
The first study found that adding Avastin to average chemotherapy (carboplatin and paclitaxel) and continuing with "maintenance" Avastin after chemo absolutely slowed the time-to-disease recurrence in women with advanced ovarian cancer. Avastin is an anti-angiogenic drug, drift it interferes with a tumor's blood supply. "This is the first molecular-targeted and first anti-angiogenesis treatment to demonstrate benefit in this population and, combined with chemotherapy followed by Avastin maintenance, should be considered as one typical option for women with this disease," said lead researcher Dr Robert A Burger, overseer of the Women's Cancer Center at Fox Chase Cancer Center in Philadelphia.
So "This is a untrained potential treatment paradigm for stage 3 and 4 ovarian cancer," added Dr Jennifer Obel, an attending doctor at Northshore University Health System and chairlady of a Sunday news conference at which these results were presented. The phase 3 con involved almost 1,900 women with stage 3 and stage 4 ovarian cancer. Those who received timber chemotherapy plus Avastin, and then maintenance Avastin, for up to 10 months lived just over 14 months without their contagion progressing compared with about 10 months for those receiving standard chemotherapy alone.
Those who received chemo extra Avastin but no maintenance drug lived without a recurrence for 11,3 months, a diversity not considered statistically significant. "I'm cautiously optimistic about this data. It without doubt shows that those who had maintenance Avastin had improved profession-free survival," said Dr Robert Morgan, co-director of the gynecologic oncology program at City of Hope Cancer Center in Duarte, Calif. "I dream we have to hold on for longer term outcomes before we make definite conclusions. It's too beforehand for overall survival benefit data".
However, he pointed out, a four-month difference for progression-free survival is "substantial". Doctors are already using Avastin off-label universally to treat ovarian cancer although it is not yet approved for this use. It has been shown to be more dynamic in this cancer than in many cancers for which it is approved.
New probe supports unconventional ways to treat ovarian and prostate cancer, while producing a dejection for those with a certain form of colon cancer. Both the ovarian and prostate cancer trials could replace clinical practice, with more women taking the drug bevacizumab (Avastin) to combat the disease in its advanced stages and more men getting shedding therapy for locally advanced prostate cancer, according to researchers who presented the findings Sunday at the American Society of Clinical Oncology (ASCO) annual intersection in Chicago. A third trial, looking at the effectiveness of cetuximab (Erbitux) in treating sure colon cancer patients, found the numb made little difference to their survival.
The first study found that adding Avastin to average chemotherapy (carboplatin and paclitaxel) and continuing with "maintenance" Avastin after chemo absolutely slowed the time-to-disease recurrence in women with advanced ovarian cancer. Avastin is an anti-angiogenic drug, drift it interferes with a tumor's blood supply. "This is the first molecular-targeted and first anti-angiogenesis treatment to demonstrate benefit in this population and, combined with chemotherapy followed by Avastin maintenance, should be considered as one typical option for women with this disease," said lead researcher Dr Robert A Burger, overseer of the Women's Cancer Center at Fox Chase Cancer Center in Philadelphia.
So "This is a untrained potential treatment paradigm for stage 3 and 4 ovarian cancer," added Dr Jennifer Obel, an attending doctor at Northshore University Health System and chairlady of a Sunday news conference at which these results were presented. The phase 3 con involved almost 1,900 women with stage 3 and stage 4 ovarian cancer. Those who received timber chemotherapy plus Avastin, and then maintenance Avastin, for up to 10 months lived just over 14 months without their contagion progressing compared with about 10 months for those receiving standard chemotherapy alone.
Those who received chemo extra Avastin but no maintenance drug lived without a recurrence for 11,3 months, a diversity not considered statistically significant. "I'm cautiously optimistic about this data. It without doubt shows that those who had maintenance Avastin had improved profession-free survival," said Dr Robert Morgan, co-director of the gynecologic oncology program at City of Hope Cancer Center in Duarte, Calif. "I dream we have to hold on for longer term outcomes before we make definite conclusions. It's too beforehand for overall survival benefit data".
However, he pointed out, a four-month difference for progression-free survival is "substantial". Doctors are already using Avastin off-label universally to treat ovarian cancer although it is not yet approved for this use. It has been shown to be more dynamic in this cancer than in many cancers for which it is approved.
Sunday 17 December 2017
Infection With Ascaris Eggs Relieves Symptoms Of Ulcerative Colitis
Infection With Ascaris Eggs Relieves Symptoms Of Ulcerative Colitis.
The specimen of a mankind who swallowed parasite eggs to treat his ulcerative colitis - and really got better - sheds light on how "worm therapy" might help heal the gut, a callow study suggests. "Our findings in this case report suggest that infection with the eggs of the T trichiura roundworm can alleviate the symptoms of ulcerative colitis," said weigh leader P'ng Loke, an aide professor in the department of medical parasitology at NYU Langone Medical Center. A accommodating parasite, Trichuris trichiura infects the large intestine.
The findings could also lead to additional ways to treat the debilitating disease, a form of inflammatory bowel disease (IBD) currently treated with drugs that don't always industry and can cause serious side effects, said Loke. The contemplation findings are published in the Dec 1, 2010 issue of Science Translational Medicine.
Loke and his side followed a 35-year-old man with severe colitis who tried worm (or "helminthic") psychoanalysis to avoid surgical removal of his entire colon. He researched the therapy, flew to a heal in Thailand who had agreed to give him the eggs, and swallowed 1500 of them.
The man contacted Loke after his self-treatment and "was essentially symptom-free". Intrigued, he and his colleagues sure to follow the man's condition.
The study analyzed slides and samples of the man's blood and colon web from 2003, before he swallowed the eggs, to 2009, a few years after ingestion. During this period, he was practically symptom-free for almost three years. When his colitis flared in 2008, he swallowed another 2000 eggs and got better again, said Loke.
Tissue captivated during lively colitis showed a large number of CD4+ T-cells, which are immune cells that produce the inflammatory protein interleukin-17, the yoke found. However, tissue taken after worm therapy, when his colitis was in remission, contained lots of T-cells that commission interleukin-22 (IL-22), a protein that promotes wound healing.
The specimen of a mankind who swallowed parasite eggs to treat his ulcerative colitis - and really got better - sheds light on how "worm therapy" might help heal the gut, a callow study suggests. "Our findings in this case report suggest that infection with the eggs of the T trichiura roundworm can alleviate the symptoms of ulcerative colitis," said weigh leader P'ng Loke, an aide professor in the department of medical parasitology at NYU Langone Medical Center. A accommodating parasite, Trichuris trichiura infects the large intestine.
The findings could also lead to additional ways to treat the debilitating disease, a form of inflammatory bowel disease (IBD) currently treated with drugs that don't always industry and can cause serious side effects, said Loke. The contemplation findings are published in the Dec 1, 2010 issue of Science Translational Medicine.
Loke and his side followed a 35-year-old man with severe colitis who tried worm (or "helminthic") psychoanalysis to avoid surgical removal of his entire colon. He researched the therapy, flew to a heal in Thailand who had agreed to give him the eggs, and swallowed 1500 of them.
The man contacted Loke after his self-treatment and "was essentially symptom-free". Intrigued, he and his colleagues sure to follow the man's condition.
The study analyzed slides and samples of the man's blood and colon web from 2003, before he swallowed the eggs, to 2009, a few years after ingestion. During this period, he was practically symptom-free for almost three years. When his colitis flared in 2008, he swallowed another 2000 eggs and got better again, said Loke.
Tissue captivated during lively colitis showed a large number of CD4+ T-cells, which are immune cells that produce the inflammatory protein interleukin-17, the yoke found. However, tissue taken after worm therapy, when his colitis was in remission, contained lots of T-cells that commission interleukin-22 (IL-22), a protein that promotes wound healing.
Saturday 2 September 2017
Gene Therapy Is Promising For The Treatment Of HIV
Gene Therapy Is Promising For The Treatment Of HIV.
Researchers surface they've moved a footstep closer to treating HIV patients with gene remedy that could potentially one day keep the AIDS-causing virus at bay. The study, published in the June 16 outgoing of the journal Science Translational Medicine, only looked at one step of the gene psychotherapy process, and there's no guarantee that genetically manipulating a patient's own cells will be successor or work better than existing drug therapies. Still, "we demonstrated that we could make this happen," said learn lead author David L DiGiusto, a biologist and immunologist at City of Hope, a medical centre and research center in Duarte, Calif.
And the research took place in people, not in investigation tubes. Scientists are considering gene therapy as a treatment for a variety of diseases, including cancer. One make advances involves inserting engineered genes into the body to change its response to illness. In the redesigned study, researchers genetically manipulated blood cells to resist HIV and inserted them into four HIV-positive patients who had lymphoma, a blood cancer.
The patients' strong blood cells had been stored earlier and were being transplanted to premium the lymphoma. Ideally, the cells would multiply and fight off HIV infection. In that case, "the virus has nowhere to grow, no style to expand in the patient". At this ahead point in the research process, however, the goal was to see if the implanted cells would survive. They did, extant in the bloodstreams of the subjects for two years.
Researchers surface they've moved a footstep closer to treating HIV patients with gene remedy that could potentially one day keep the AIDS-causing virus at bay. The study, published in the June 16 outgoing of the journal Science Translational Medicine, only looked at one step of the gene psychotherapy process, and there's no guarantee that genetically manipulating a patient's own cells will be successor or work better than existing drug therapies. Still, "we demonstrated that we could make this happen," said learn lead author David L DiGiusto, a biologist and immunologist at City of Hope, a medical centre and research center in Duarte, Calif.
And the research took place in people, not in investigation tubes. Scientists are considering gene therapy as a treatment for a variety of diseases, including cancer. One make advances involves inserting engineered genes into the body to change its response to illness. In the redesigned study, researchers genetically manipulated blood cells to resist HIV and inserted them into four HIV-positive patients who had lymphoma, a blood cancer.
The patients' strong blood cells had been stored earlier and were being transplanted to premium the lymphoma. Ideally, the cells would multiply and fight off HIV infection. In that case, "the virus has nowhere to grow, no style to expand in the patient". At this ahead point in the research process, however, the goal was to see if the implanted cells would survive. They did, extant in the bloodstreams of the subjects for two years.
Tuesday 27 June 2017
Using Statins To Lower Cholesterol May Be More Beneficial Way To Prevent Heart Attack And Stroke
Using Statins To Lower Cholesterol May Be More Beneficial Way To Prevent Heart Attack And Stroke.
Broader use of cholesterol-lowering statins may be a cost-effective scheme to halt humanitarianism attack and stroke, US researchers suggest. In the study, published online Sept 27, 2010 in the catalogue Circulation. The researchers also found that screening for dear sensitivity C-reactive protein (CRP) to identify patients who may benefit from statin group therapy is only cost-effective in certain cases.
Elevated levels of CRP indicate inflammation and suggest an increased gamble for heart attack and stroke. Currently, statin therapy is recommended for high-risk patients - those with a 20 percent or greater danger of some type of cardiovascular event within the next 10 years.
Broader use of cholesterol-lowering statins may be a cost-effective scheme to halt humanitarianism attack and stroke, US researchers suggest. In the study, published online Sept 27, 2010 in the catalogue Circulation. The researchers also found that screening for dear sensitivity C-reactive protein (CRP) to identify patients who may benefit from statin group therapy is only cost-effective in certain cases.
Elevated levels of CRP indicate inflammation and suggest an increased gamble for heart attack and stroke. Currently, statin therapy is recommended for high-risk patients - those with a 20 percent or greater danger of some type of cardiovascular event within the next 10 years.
Thursday 22 June 2017
Device Resynchronization Therapy-Defibrillator Prolongs Life Of Patients With Heart Failure
Device Resynchronization Therapy-Defibrillator Prolongs Life Of Patients With Heart Failure.
Canadian researchers on that an implantable badge called a resynchronization therapy-defibrillator helps remain the left side of the heart pumping properly, extending the life of heart breakdown patients. Cardiac-resynchronization therapy, or CRT-D, also reduces heart failure symptoms, such as edema (swelling) and shortness of breath, as well as hospitalizations for some patients with reasonable to severe heart failure, the scientists added. "The unharmed idea of the therapy is to try to resynchronize the heart," said lead researcher Dr Anthony SL Tang, from the University of British Columbia in Vancouver.
It improves the heart's skill to pact and pump blood throughout the body. This study demonstrates that, in adding up to symptom relief, the CRT-D extends life and keeps heart failure patients out of the hospital. Tang added that patients will endure to need medical therapy and an implantable cardioverter-defibrillator (ICD) in totting up to a CRT-D.
And "We are saying people who are receiving good medical therapy and are now active to get a defibrillator, please go ahead and also do resynchronization therapy as well. This is worthwhile, because they will live longer and be more like as not to stay out of the hospital". The report is published in the Nov 14, 2010 online number of the New England Journal of Medicine, to coincide with a scheduled presentation of the findings Sunday at the American Heart Association annual session in Chicago.
Tang's team randomly assigned 1,798 patients with bland or moderate heart failure to have a CRT-D plus an ICD implanted or only an ICD implanted. Over 40 months of follow-up, the researchers found that those who received both devices capable a 29 percent reduction in their symptoms, compared with patients who did not be given the resynchronization device. In addition, there was a 27 percent reduction in deaths and guts failure hospitalizations among those who also had a CRT-D, they found.
More than 22 million kinfolk worldwide, including 6 million patients in the United States, endure from heart failure. These patients' hearts cannot adequately pump blood through the body. And although deaths from humanity disease have fallen over the last three decades, the death bawl out for heart failure is rising, the researchers said. Treating heart failure is also expensive, costing an estimated $40 billion each year in the United States alone.
In cardiac-resynchronization therapy, a stopwatch-sized artifice is implanted in the loftier chest to resynchronize the contractions of the heart's upper chambers, called ventricles. This is done by sending electrical impulses to the empathy muscle. Resynchronizing the contractions of the ventricles can relieve the heart pump blood throughout the body more efficiently.
Canadian researchers on that an implantable badge called a resynchronization therapy-defibrillator helps remain the left side of the heart pumping properly, extending the life of heart breakdown patients. Cardiac-resynchronization therapy, or CRT-D, also reduces heart failure symptoms, such as edema (swelling) and shortness of breath, as well as hospitalizations for some patients with reasonable to severe heart failure, the scientists added. "The unharmed idea of the therapy is to try to resynchronize the heart," said lead researcher Dr Anthony SL Tang, from the University of British Columbia in Vancouver.
It improves the heart's skill to pact and pump blood throughout the body. This study demonstrates that, in adding up to symptom relief, the CRT-D extends life and keeps heart failure patients out of the hospital. Tang added that patients will endure to need medical therapy and an implantable cardioverter-defibrillator (ICD) in totting up to a CRT-D.
And "We are saying people who are receiving good medical therapy and are now active to get a defibrillator, please go ahead and also do resynchronization therapy as well. This is worthwhile, because they will live longer and be more like as not to stay out of the hospital". The report is published in the Nov 14, 2010 online number of the New England Journal of Medicine, to coincide with a scheduled presentation of the findings Sunday at the American Heart Association annual session in Chicago.
Tang's team randomly assigned 1,798 patients with bland or moderate heart failure to have a CRT-D plus an ICD implanted or only an ICD implanted. Over 40 months of follow-up, the researchers found that those who received both devices capable a 29 percent reduction in their symptoms, compared with patients who did not be given the resynchronization device. In addition, there was a 27 percent reduction in deaths and guts failure hospitalizations among those who also had a CRT-D, they found.
More than 22 million kinfolk worldwide, including 6 million patients in the United States, endure from heart failure. These patients' hearts cannot adequately pump blood through the body. And although deaths from humanity disease have fallen over the last three decades, the death bawl out for heart failure is rising, the researchers said. Treating heart failure is also expensive, costing an estimated $40 billion each year in the United States alone.
In cardiac-resynchronization therapy, a stopwatch-sized artifice is implanted in the loftier chest to resynchronize the contractions of the heart's upper chambers, called ventricles. This is done by sending electrical impulses to the empathy muscle. Resynchronizing the contractions of the ventricles can relieve the heart pump blood throughout the body more efficiently.
Thursday 1 June 2017
Gene Therapy In Children
Gene Therapy In Children.
Using gene therapy, German researchers narrative that they managed to "correct" a malfunctioning gene answerable for Wiskott-Aldrich syndrome, a rare but enthralling childhood disorder that leads to prolonged bleeding from even minor hits or scrapes, and also leaves these children weak to certain cancers and dangerous infections. However, one of the 10 kids in the study developed sharp T-cell leukemia, apparently as a result of the viral vector that was used to insert the salutary gene. The boy is currently on chemotherapy, the study authors noted.
This is a very good key step, but it's a little scary and we need to move to safer vectors - said Dr Mary Ellen Conley, concert-master of the Program in Genetic Immunodeficiencies at St Jude Children's Research Hospital in Memphis, Tenn. "The lucubrate shows proof-of-principle that gene remedial programme with stem cells in a genetic disorder like this has strong potential," added Paul Sanberg, a stop cell specialist who is director of the University of South Florida Center of Excellence for Aging and Brain Repair in Tampa. Neither Conley nor Sanberg were affected in the study, which is scheduled to be presented Sunday at the annual convention of the American Society of Hematology in Orlando, Fla.
According to Conley, children (mostly boys) with Wiskott-Aldrich syndrome (WAS) are born with an inherited genetic inadequacy on the X chromosome that affects the numeral and size of platelets and makes the children remarkably credulous to easy bleeding and infections, including different types of cancer. Bone marrow transplants are the important treatment for the disorder which, if they succeed, basically cure the patient. "They become larger up, go to college and they cause problems. But they're not an easy group of patients to transplant".
Using gene therapy, German researchers narrative that they managed to "correct" a malfunctioning gene answerable for Wiskott-Aldrich syndrome, a rare but enthralling childhood disorder that leads to prolonged bleeding from even minor hits or scrapes, and also leaves these children weak to certain cancers and dangerous infections. However, one of the 10 kids in the study developed sharp T-cell leukemia, apparently as a result of the viral vector that was used to insert the salutary gene. The boy is currently on chemotherapy, the study authors noted.
This is a very good key step, but it's a little scary and we need to move to safer vectors - said Dr Mary Ellen Conley, concert-master of the Program in Genetic Immunodeficiencies at St Jude Children's Research Hospital in Memphis, Tenn. "The lucubrate shows proof-of-principle that gene remedial programme with stem cells in a genetic disorder like this has strong potential," added Paul Sanberg, a stop cell specialist who is director of the University of South Florida Center of Excellence for Aging and Brain Repair in Tampa. Neither Conley nor Sanberg were affected in the study, which is scheduled to be presented Sunday at the annual convention of the American Society of Hematology in Orlando, Fla.
According to Conley, children (mostly boys) with Wiskott-Aldrich syndrome (WAS) are born with an inherited genetic inadequacy on the X chromosome that affects the numeral and size of platelets and makes the children remarkably credulous to easy bleeding and infections, including different types of cancer. Bone marrow transplants are the important treatment for the disorder which, if they succeed, basically cure the patient. "They become larger up, go to college and they cause problems. But they're not an easy group of patients to transplant".
Wednesday 8 March 2017
An Effect Of Hormone Therapy On Breast Cancer
An Effect Of Hormone Therapy On Breast Cancer.
Although several overweight studies in latest years have linked the use of hormone therapy after menopause with an increased danger of breast cancer, the authors of a new analysis claim the evidence is too limited to confirm the connection. Dr Samuel Shapiro, of the University of Cape Town Medical School in South Africa, and his colleagues took another air at three eminently studies that investigated hormone therapy and its credible health risks - the Collaborative Reanalysis, the Women's Health Initiative (WHI) and the Million Women Study. Together, the results of these studies found overall an increased jeopardize of breast cancer centre of women who used the combination form of hormone therapy with both estrogen and progesterone.
Women who have had a hysterectomy and use estrogen-only group therapy also have an increased risk, two of the studies found. The WHI, however, found that estrogen-only remedy may not increase breast cancer risk and may actually decrease it, although that has not been confirmed in other research. After the WHI scrutinize was published in July 2002, women dropped hormone cure in droves.
Many experts pointed to that decline in hormone therapy use as the reason breast cancer rates were declining. Not so, Shapiro said: "The declivity in breast cancer extent started three years before the fall in HRT use commenced, lasted for only one year after the HRT dab commenced, and then stopped". For instance between 2002 and 2003, when large numbers of women were still using hormone therapy, the numeral of new breast cancer cases fell by nearly 7 percent.
In taking a bearing at the three studies again, Shapiro and his team reviewed whether the evidence satisfied criteria superior to researchers, such as the strength of an association, taking into account other factors that could influence risk. Their conclusion: The fact is not strong enough to say definitively that hormone therapy causes breast cancer. The go into is published in the current issue of the Journal of Family Planning and Reproductive Health Care.
Although several overweight studies in latest years have linked the use of hormone therapy after menopause with an increased danger of breast cancer, the authors of a new analysis claim the evidence is too limited to confirm the connection. Dr Samuel Shapiro, of the University of Cape Town Medical School in South Africa, and his colleagues took another air at three eminently studies that investigated hormone therapy and its credible health risks - the Collaborative Reanalysis, the Women's Health Initiative (WHI) and the Million Women Study. Together, the results of these studies found overall an increased jeopardize of breast cancer centre of women who used the combination form of hormone therapy with both estrogen and progesterone.
Women who have had a hysterectomy and use estrogen-only group therapy also have an increased risk, two of the studies found. The WHI, however, found that estrogen-only remedy may not increase breast cancer risk and may actually decrease it, although that has not been confirmed in other research. After the WHI scrutinize was published in July 2002, women dropped hormone cure in droves.
Many experts pointed to that decline in hormone therapy use as the reason breast cancer rates were declining. Not so, Shapiro said: "The declivity in breast cancer extent started three years before the fall in HRT use commenced, lasted for only one year after the HRT dab commenced, and then stopped". For instance between 2002 and 2003, when large numbers of women were still using hormone therapy, the numeral of new breast cancer cases fell by nearly 7 percent.
In taking a bearing at the three studies again, Shapiro and his team reviewed whether the evidence satisfied criteria superior to researchers, such as the strength of an association, taking into account other factors that could influence risk. Their conclusion: The fact is not strong enough to say definitively that hormone therapy causes breast cancer. The go into is published in the current issue of the Journal of Family Planning and Reproductive Health Care.
Friday 17 February 2017
Therapeutic Talking With The Doctor After A Stroke Can Help To Survive
Therapeutic Talking With The Doctor After A Stroke Can Help To Survive.
After misery a stroke, patients who disparage with a therapist about their hopes and fears about the tomorrow are less depressed and live longer than patients who don't, British researchers say. In fact, 48 percent of the nation who participated in these motivational interviews within the first month after a act were not depressed a year later, compared to 37,7 of the patients who were not involved in talk therapy. In addition, only 6,5 percent of those interested in talk therapy died within the year, compared with 12,8 percent of patients who didn't learn the therapy, the investigators found.
So "The talk-based intervention is based on portion people to adjust to the consequences of their stroke so they are less likely to be depressed," said guide researcher Caroline Watkins, a professor of stroke and elder care at the University of Central Lancashire. Depression is universal after a stroke, affecting about 40 to 50 percent of patients. Of these, about 20 percent will decline major depression.
Depression, which can lead to apathy, social withdrawal and even suicide, is one of the biggest obstacles to solid and mental recovery after a stroke, researchers say. Watkins believes their come near is unique. "Psychological interventions haven't been shown to be effective, although it seems like a well-thought-out thing. This is the first time a talk-based therapy has been shown to be effective.
One reason, the researchers noted, is that the group therapy began a month after the stroke, earlier than other trials of psychological counseling. They speculated that with later interventions, sadness had already set in and may have interfered with recovery.
Early therapy, Watkins has said, can help occupy set realistic expectations "and avoid some of the misery of life after stroke". The report was published in the July exit of Stroke. For the study, the researchers randomly assigned half of 411 example patients to see a therapist for up to four 30- to 60-minute sessions and the other half to no visits with a therapist.
After misery a stroke, patients who disparage with a therapist about their hopes and fears about the tomorrow are less depressed and live longer than patients who don't, British researchers say. In fact, 48 percent of the nation who participated in these motivational interviews within the first month after a act were not depressed a year later, compared to 37,7 of the patients who were not involved in talk therapy. In addition, only 6,5 percent of those interested in talk therapy died within the year, compared with 12,8 percent of patients who didn't learn the therapy, the investigators found.
So "The talk-based intervention is based on portion people to adjust to the consequences of their stroke so they are less likely to be depressed," said guide researcher Caroline Watkins, a professor of stroke and elder care at the University of Central Lancashire. Depression is universal after a stroke, affecting about 40 to 50 percent of patients. Of these, about 20 percent will decline major depression.
Depression, which can lead to apathy, social withdrawal and even suicide, is one of the biggest obstacles to solid and mental recovery after a stroke, researchers say. Watkins believes their come near is unique. "Psychological interventions haven't been shown to be effective, although it seems like a well-thought-out thing. This is the first time a talk-based therapy has been shown to be effective.
One reason, the researchers noted, is that the group therapy began a month after the stroke, earlier than other trials of psychological counseling. They speculated that with later interventions, sadness had already set in and may have interfered with recovery.
Early therapy, Watkins has said, can help occupy set realistic expectations "and avoid some of the misery of life after stroke". The report was published in the July exit of Stroke. For the study, the researchers randomly assigned half of 411 example patients to see a therapist for up to four 30- to 60-minute sessions and the other half to no visits with a therapist.
Friday 19 August 2016
New Drug To Curb Hepatitis C
New Drug To Curb Hepatitis C.
The recently approved soporific Incivek, combined with two norm drugs, is highly effective at treating hepatitis C, a notoriously difficult-to-manage liver disease, two strange studies show. The dull works not only in patients just starting treatment, but in those who failed earlier treatment, the research found. The hepatitis C virus can skulk in the body for years, causing liver damage, cirrhosis and even liver failure. "This is a significant go on in the treatment of hepatitis C," said Dr David Bernstein, outstanding of the division of gastroenterology, hepatology and nutrition at North Shore University Hospital in Manhasset NY, who was not active in either study.
And "We know that if we can get rid of the hepatitis C, we can anticipate the progression of liver disease. This means we can prevent the progression of cirrhosis, we can prevent the development of cancer and also frustrate the need for liver transplantation in a large number of people".
Incivek (telaprevir) was approved by the US Food and Drug Administration in May and is the help drug in a class of drugs called protease inhibitors to be approved to contest hepatitis C The other drug, called Victrelis (boceprevir), was also approved in May. The set treatment for hepatitis C has been a combination of two drugs, pegylated-interferon and ribavirin, which are given for a year.
If protease inhibitors such as Incivek are added to the mix, the "viral cure" grade improves and the therapy time is reduced to six months, researchers found. Both reports were published in the June 23 online copy of the New England Journal of Medicine.
In one study, a Phase 3 go known as ADVANCE, patients were randomly assigned to either a placebo or the healing in a double-blind study, which means that neither the patients nor the researchers know who's getting the drug and who's getting a mock treatment. This type of study is considered the gold standard for clinical research.
In the ADVANCE trial, 1088 patients with hepatitis C who had never been treated for the state were randomly assigned to criterion therapy for 48 weeks, or telaprevir combined with standard therapy for eight or for 12 weeks, followed by touchstone therapy alone for a total treatment time of either 24 or 48 weeks. The researchers found that 79 percent of those receiving Incivek for the longest days (24 weeks) had a "sustained response," which basically means their hepatitis C was contained.
The recently approved soporific Incivek, combined with two norm drugs, is highly effective at treating hepatitis C, a notoriously difficult-to-manage liver disease, two strange studies show. The dull works not only in patients just starting treatment, but in those who failed earlier treatment, the research found. The hepatitis C virus can skulk in the body for years, causing liver damage, cirrhosis and even liver failure. "This is a significant go on in the treatment of hepatitis C," said Dr David Bernstein, outstanding of the division of gastroenterology, hepatology and nutrition at North Shore University Hospital in Manhasset NY, who was not active in either study.
And "We know that if we can get rid of the hepatitis C, we can anticipate the progression of liver disease. This means we can prevent the progression of cirrhosis, we can prevent the development of cancer and also frustrate the need for liver transplantation in a large number of people".
Incivek (telaprevir) was approved by the US Food and Drug Administration in May and is the help drug in a class of drugs called protease inhibitors to be approved to contest hepatitis C The other drug, called Victrelis (boceprevir), was also approved in May. The set treatment for hepatitis C has been a combination of two drugs, pegylated-interferon and ribavirin, which are given for a year.
If protease inhibitors such as Incivek are added to the mix, the "viral cure" grade improves and the therapy time is reduced to six months, researchers found. Both reports were published in the June 23 online copy of the New England Journal of Medicine.
In one study, a Phase 3 go known as ADVANCE, patients were randomly assigned to either a placebo or the healing in a double-blind study, which means that neither the patients nor the researchers know who's getting the drug and who's getting a mock treatment. This type of study is considered the gold standard for clinical research.
In the ADVANCE trial, 1088 patients with hepatitis C who had never been treated for the state were randomly assigned to criterion therapy for 48 weeks, or telaprevir combined with standard therapy for eight or for 12 weeks, followed by touchstone therapy alone for a total treatment time of either 24 or 48 weeks. The researchers found that 79 percent of those receiving Incivek for the longest days (24 weeks) had a "sustained response," which basically means their hepatitis C was contained.
Tuesday 29 December 2015
To Alleviate Pain Associated With Arthritis Should Definitely Exercise
To Alleviate Pain Associated With Arthritis Should Definitely Exercise.
Patients with knee or in osteoarthritis traveller better if they continue to do their physical therapy exercises after completing a supervised perturb therapy at a medical facility, new research indicates. The Dutch chew over also found that arthritis patients reported less pain, improved muscle strength and a better range of change when they followed their provider's recommendations for overall exercise (such as walking) and a physically active lifestyle - a desirable that improved the long-range effectiveness of supervised therapy.
The findings, reported online and in the August etching issue of Arthritis Care & Research, stem from work conducted by a team of researchers led by Martijn Pisters of the Netherlands Institute for Health Services Research and the University Medical Center Utrecht in the Netherlands. The meditate on authors esteemed in a news release from the journal's publisher that the World Health Organization deems osteoarthritis (OA) to be one of the 10 most disabling conditions in the developed world.
Four in five OA patients have decrease limitations, the WHO estimates, while one-quarter cannot bargain in the reasonable routines of daily living - an ordeal for which physical therapy is often the prescribed short-term remedy. To assess how well patients do after supervised therapy, Pisters and his colleagues tracked 150 wise and/or knee OA patients for five years.
Patients with knee or in osteoarthritis traveller better if they continue to do their physical therapy exercises after completing a supervised perturb therapy at a medical facility, new research indicates. The Dutch chew over also found that arthritis patients reported less pain, improved muscle strength and a better range of change when they followed their provider's recommendations for overall exercise (such as walking) and a physically active lifestyle - a desirable that improved the long-range effectiveness of supervised therapy.
The findings, reported online and in the August etching issue of Arthritis Care & Research, stem from work conducted by a team of researchers led by Martijn Pisters of the Netherlands Institute for Health Services Research and the University Medical Center Utrecht in the Netherlands. The meditate on authors esteemed in a news release from the journal's publisher that the World Health Organization deems osteoarthritis (OA) to be one of the 10 most disabling conditions in the developed world.
Four in five OA patients have decrease limitations, the WHO estimates, while one-quarter cannot bargain in the reasonable routines of daily living - an ordeal for which physical therapy is often the prescribed short-term remedy. To assess how well patients do after supervised therapy, Pisters and his colleagues tracked 150 wise and/or knee OA patients for five years.
Tuesday 15 December 2015
Increased Risk Of Major And Minor Bleeding During Antiplatelet Therapy
Increased Risk Of Major And Minor Bleeding During Antiplatelet Therapy.
Risk of bleeding for patients on antiplatelet psychotherapy with either warfarin or a party of Plavix (clopidogrel) and aspirin is substantial, a redone study finds. Both therapies are prescribed for millions of Americans to interdict life-threatening blood clots, especially after a heart attack or stroke. But the Plavix-aspirin conjunction was thought to cause less bleeding than it actually does, the researchers say.
And "As with all drugs, these drugs come with risks; the most importance is bleeding," said lead author Dr Nadine Shehab, from the US Centers for Disease Control and Prevention (CDC). While the endanger of bleeding from warfarin is well-known, the risks associated with dual remedy were not well understood. "We found that the risk for hemorrhage was threefold higher for warfarin than for dual antiplatelet therapy. We expected that because warfarin is prescribed much more continually than dual antiplatelet therapy".
However, when the researchers took the billion of prescriptions into account, the gap between warfarin and dual antiplatelet group therapy shrank. "And this was worrisome". For both regimens, the number of hospital admissions because of bleeding was similar. And bleeding-related visits to predicament department visits were only 50 percent decrease for those on dual antiplatelet therapy compared with warfarin. "This isn't as big a difference as we had thought".
For the study, published Monday in the Archives of Internal Medicine, Shehab's yoke used national databases to pigeon-hole emergency department visits for bleeding caused by either dual antiplatelet therapy or warfarin between 2006 and 2008. The investigators found 384 annual exigency department visits for bleeding to each patients taking dual antiplatelet therapy and 2,926 annual visits for those taking warfarin.
Risk of bleeding for patients on antiplatelet psychotherapy with either warfarin or a party of Plavix (clopidogrel) and aspirin is substantial, a redone study finds. Both therapies are prescribed for millions of Americans to interdict life-threatening blood clots, especially after a heart attack or stroke. But the Plavix-aspirin conjunction was thought to cause less bleeding than it actually does, the researchers say.
And "As with all drugs, these drugs come with risks; the most importance is bleeding," said lead author Dr Nadine Shehab, from the US Centers for Disease Control and Prevention (CDC). While the endanger of bleeding from warfarin is well-known, the risks associated with dual remedy were not well understood. "We found that the risk for hemorrhage was threefold higher for warfarin than for dual antiplatelet therapy. We expected that because warfarin is prescribed much more continually than dual antiplatelet therapy".
However, when the researchers took the billion of prescriptions into account, the gap between warfarin and dual antiplatelet group therapy shrank. "And this was worrisome". For both regimens, the number of hospital admissions because of bleeding was similar. And bleeding-related visits to predicament department visits were only 50 percent decrease for those on dual antiplatelet therapy compared with warfarin. "This isn't as big a difference as we had thought".
For the study, published Monday in the Archives of Internal Medicine, Shehab's yoke used national databases to pigeon-hole emergency department visits for bleeding caused by either dual antiplatelet therapy or warfarin between 2006 and 2008. The investigators found 384 annual exigency department visits for bleeding to each patients taking dual antiplatelet therapy and 2,926 annual visits for those taking warfarin.
Monday 9 November 2015
Doctors Recommend Carefully Treat Tinnitus
Doctors Recommend Carefully Treat Tinnitus.
Patients tribulation from the intense, lingering and sometimes untreatable ringing in the ear known as tinnitus may get some relief from a new combination therapy, opening research suggests. The study looked at treatment with daily targeted electrical stimulation of the body's on edge system paired with sound therapy. Half of the procedure - "vagus slang balls stimulation" - centers on direct stimulation of the vagus nerve, one of 12 cranial nerves that winds its modus vivendi through the abdomen, lungs, heart and brain stem.
Patients are also exposed to "tone therapy" - carefully selected tones that misrepresent outside the frequency vary of the troubling ear-ringing condition. Indications of the new treatment's success, however, are so far based on a very uncharitable pool of patients, and relief was not universal. "Half of the participants demonstrated large decreases in their tinnitus symptoms, with three of them showing a 44 percent reduction in the import of tinnitus on their daily lives," said swotting co-author Sven Vanneste.
But, "five participants, all of whom were on medications for other problems, did not show significant changes". For those participants, anaesthetize interactions might have blocked the therapy's impact, Vanneste suggested. "However, further inquire into needs to be conducted to confirm this," said Vanneste, an associate professor at the School of Behavioral and Brain Sciences at the University of Texas at Dallas. The study, conducted in collaboration with researchers at the University Hospital Antwerp, in Belgium, appeared in a late-model go forth of the journal Neuromodulation: Technology at the Neural Interface.
The authors disclosed that two members of the inspect team have a uninhibited connection with MicroTransponder Inc, the manufacturer of the neurostimulation software used to deliver vagus staunchness stimulation therapy. One researcher is a MicroTransponder employee, the other a consultant. Vanneste himself has no connection with the company.
According to the US National Institute on Deafness and Other Communication Disorders, nearly 23 million American adults have at some item struggled with sensitivity ringing for periods extending beyond three months. Yet tinnitus is not considered to be a illness in itself, but rather an indication of trouble somewhere along the auditory nerve pathway. Noise-sparked hearing detriment can set off ringing, as can ear/sinus infection, brain tumors, heart disease, hormonal imbalances, thyroid problems and medical complications.
A handful of treatments are available. The two most renowned are "cognitive behavioral therapy" (to promote relaxation and mindfulness) and "tinnitus retraining therapy" (to essentially false flag the ringing with more neutral sounds). In 2012, a Dutch set investigated a combination of both approaches, and found that the combined therapy process did seem to reduce debilitation and improve patients' quality of life better than either intervention alone.
Patients tribulation from the intense, lingering and sometimes untreatable ringing in the ear known as tinnitus may get some relief from a new combination therapy, opening research suggests. The study looked at treatment with daily targeted electrical stimulation of the body's on edge system paired with sound therapy. Half of the procedure - "vagus slang balls stimulation" - centers on direct stimulation of the vagus nerve, one of 12 cranial nerves that winds its modus vivendi through the abdomen, lungs, heart and brain stem.
Patients are also exposed to "tone therapy" - carefully selected tones that misrepresent outside the frequency vary of the troubling ear-ringing condition. Indications of the new treatment's success, however, are so far based on a very uncharitable pool of patients, and relief was not universal. "Half of the participants demonstrated large decreases in their tinnitus symptoms, with three of them showing a 44 percent reduction in the import of tinnitus on their daily lives," said swotting co-author Sven Vanneste.
But, "five participants, all of whom were on medications for other problems, did not show significant changes". For those participants, anaesthetize interactions might have blocked the therapy's impact, Vanneste suggested. "However, further inquire into needs to be conducted to confirm this," said Vanneste, an associate professor at the School of Behavioral and Brain Sciences at the University of Texas at Dallas. The study, conducted in collaboration with researchers at the University Hospital Antwerp, in Belgium, appeared in a late-model go forth of the journal Neuromodulation: Technology at the Neural Interface.
The authors disclosed that two members of the inspect team have a uninhibited connection with MicroTransponder Inc, the manufacturer of the neurostimulation software used to deliver vagus staunchness stimulation therapy. One researcher is a MicroTransponder employee, the other a consultant. Vanneste himself has no connection with the company.
According to the US National Institute on Deafness and Other Communication Disorders, nearly 23 million American adults have at some item struggled with sensitivity ringing for periods extending beyond three months. Yet tinnitus is not considered to be a illness in itself, but rather an indication of trouble somewhere along the auditory nerve pathway. Noise-sparked hearing detriment can set off ringing, as can ear/sinus infection, brain tumors, heart disease, hormonal imbalances, thyroid problems and medical complications.
A handful of treatments are available. The two most renowned are "cognitive behavioral therapy" (to promote relaxation and mindfulness) and "tinnitus retraining therapy" (to essentially false flag the ringing with more neutral sounds). In 2012, a Dutch set investigated a combination of both approaches, and found that the combined therapy process did seem to reduce debilitation and improve patients' quality of life better than either intervention alone.
Thursday 15 October 2015
Psychologists Give Some Guidance To Adolescents
Psychologists Give Some Guidance To Adolescents.
Teen girls struggling with post-traumatic accent clamour stemming from sexual abuse do well when treated with a type of therapy that asks them to time and confront their traumatic memories, according to a small new study. The study's results suggest that "prolonged airing therapy," which is approved for adults, is more effective at helping adolescent girls affected post-traumatic stress disorder (PTSD) than traditional supportive counseling. "Prolonged exposure is a fount of cognitive behavior therapy in which patients are asked to recount aloud several times their traumatic experience, including details of what happened during the episode and what they thought and felt during the experience," said study founder Edna Foa, a professor of clinical psychology at the University of Pennsylvania.
And "For example, a twist that felt shame and guilt because she did not prevent her father from sexually abusing her comes to realize that she did not have the privilege to prevent her father from abusing her, and it was her father's fault, not hers, that she was abused. During repeated recounting of the traumatizing events, the patient gets closure on those events and is able to put it aside as something horrific that happened to her in the past. She can now continue to develop without being hampered by the traumatic experience".
Foa and her colleagues reported their findings in the Dec 25, 2013 pour of the Journal of the American Medical Association. The researchers focused on a congregation of 61 girls, all between the ages of 13 and 18 and all suffering from PTSD tied up to sexual abuse that had occurred at least three months before the study started. No boys were included in the research.
Roughly half of the girls were given criterion supportive counseling in weekly sessions conducted over a 14-week period. During that time, counselors aimed to cultivate a trusting relation in which the teens were allowed to address their traumatic experience only if and when they felt ready to do so. The other unaggressive group was enlisted in a prolonged exposure therapy program in which patients were encouraged to revisit the commencement of their demons in a more direct manner, albeit in a controlled environment designed to be both contemplative and sensitive.
Teen girls struggling with post-traumatic accent clamour stemming from sexual abuse do well when treated with a type of therapy that asks them to time and confront their traumatic memories, according to a small new study. The study's results suggest that "prolonged airing therapy," which is approved for adults, is more effective at helping adolescent girls affected post-traumatic stress disorder (PTSD) than traditional supportive counseling. "Prolonged exposure is a fount of cognitive behavior therapy in which patients are asked to recount aloud several times their traumatic experience, including details of what happened during the episode and what they thought and felt during the experience," said study founder Edna Foa, a professor of clinical psychology at the University of Pennsylvania.
And "For example, a twist that felt shame and guilt because she did not prevent her father from sexually abusing her comes to realize that she did not have the privilege to prevent her father from abusing her, and it was her father's fault, not hers, that she was abused. During repeated recounting of the traumatizing events, the patient gets closure on those events and is able to put it aside as something horrific that happened to her in the past. She can now continue to develop without being hampered by the traumatic experience".
Foa and her colleagues reported their findings in the Dec 25, 2013 pour of the Journal of the American Medical Association. The researchers focused on a congregation of 61 girls, all between the ages of 13 and 18 and all suffering from PTSD tied up to sexual abuse that had occurred at least three months before the study started. No boys were included in the research.
Roughly half of the girls were given criterion supportive counseling in weekly sessions conducted over a 14-week period. During that time, counselors aimed to cultivate a trusting relation in which the teens were allowed to address their traumatic experience only if and when they felt ready to do so. The other unaggressive group was enlisted in a prolonged exposure therapy program in which patients were encouraged to revisit the commencement of their demons in a more direct manner, albeit in a controlled environment designed to be both contemplative and sensitive.
Tuesday 12 May 2015
The Earlier Courses Of Multiple Sclerosis
The Earlier Courses Of Multiple Sclerosis.
A analysis that uses patients' own coarse blood cells may be able to reverse some of the effects of multiple sclerosis, a preparatory study suggests. The findings, published Tuesday in the Journal of the American Medical Association, had experts cautiously optimistic. But they also stressed that the examination was small - with around 150 patients - and the benefits were minimal to people who were in the earlier courses of multiple sclerosis (MS). "This is certainly a yes development," said Bruce Bebo, the executive vice president of enquiry for the National Multiple Sclerosis Society.
There are numerous so-called "disease-modifying" drugs available to boon MS - a disease in which the immune system mistakenly attacks the protective sheath (called myelin) around fibers in the percipience and spine, according to the society. Depending on where the damage is, symptoms embody muscle weakness, numbness, vision problems and difficulty with balance and coordination. But while those drugs can out of it the progression of MS, they can't reverse disability, said Dr Richard Burt, the take the lead researcher on the new study and chief of immunotherapy and autoimmune diseases at Northwestern University's Feinberg School of Medicine in Chicago.
His party tested a new approach: essentially, "rebooting" the unaffected system with patients' own blood-forming stem cells - primitive cells that fully grown into immune-system fighters. The researchers removed and stored stem cells from MS patients' blood, then in use relatively low-dose chemotherapy drugs to - as Burt described it - "turn down" the patients' immune-system activity. From there, the curb cells were infused back into patients' blood.
Just over 80 bodies were followed for two years after they had the procedure, according to the study. Half catch-phrase their score on a standard MS disability scale fall by one point or more, according to Burt's team. Of 36 patients who were followed for four years, nearly two-thirds aphorism that much of an improvement. Bebo said a one-point metamorphose on that scale - called the Expanded Disability Status Scale - is meaningful. "It would once and for all improve patients' quality of life".
What's more, of the patients followed for four years, 80 percent remained natural of a symptom flare-up. There are caveats, though. One is that the cure was only effective for patients with relapsing-remitting MS - where symptoms swelling up, then improve or disappear for a period of time. It was not helpful for the 27 patients with secondary-progressive MS, or those who'd had any manner of MS for more than 10 years.
A analysis that uses patients' own coarse blood cells may be able to reverse some of the effects of multiple sclerosis, a preparatory study suggests. The findings, published Tuesday in the Journal of the American Medical Association, had experts cautiously optimistic. But they also stressed that the examination was small - with around 150 patients - and the benefits were minimal to people who were in the earlier courses of multiple sclerosis (MS). "This is certainly a yes development," said Bruce Bebo, the executive vice president of enquiry for the National Multiple Sclerosis Society.
There are numerous so-called "disease-modifying" drugs available to boon MS - a disease in which the immune system mistakenly attacks the protective sheath (called myelin) around fibers in the percipience and spine, according to the society. Depending on where the damage is, symptoms embody muscle weakness, numbness, vision problems and difficulty with balance and coordination. But while those drugs can out of it the progression of MS, they can't reverse disability, said Dr Richard Burt, the take the lead researcher on the new study and chief of immunotherapy and autoimmune diseases at Northwestern University's Feinberg School of Medicine in Chicago.
His party tested a new approach: essentially, "rebooting" the unaffected system with patients' own blood-forming stem cells - primitive cells that fully grown into immune-system fighters. The researchers removed and stored stem cells from MS patients' blood, then in use relatively low-dose chemotherapy drugs to - as Burt described it - "turn down" the patients' immune-system activity. From there, the curb cells were infused back into patients' blood.
Just over 80 bodies were followed for two years after they had the procedure, according to the study. Half catch-phrase their score on a standard MS disability scale fall by one point or more, according to Burt's team. Of 36 patients who were followed for four years, nearly two-thirds aphorism that much of an improvement. Bebo said a one-point metamorphose on that scale - called the Expanded Disability Status Scale - is meaningful. "It would once and for all improve patients' quality of life".
What's more, of the patients followed for four years, 80 percent remained natural of a symptom flare-up. There are caveats, though. One is that the cure was only effective for patients with relapsing-remitting MS - where symptoms swelling up, then improve or disappear for a period of time. It was not helpful for the 27 patients with secondary-progressive MS, or those who'd had any manner of MS for more than 10 years.
Subscribe to:
Posts (Atom)